Depression in Parkinson's disease: A double-blind, randomized, placebo-controlled pilot study of omega-3 fatty-acid supplementation

Journal of Affective Disorders

Volumn 111, Issue 2-3, 2008, Pages 351-359

  da Silva, Ticyana Moralez ^a   Munhoz, Renato Puppi ^b   Alvarez, Cristiano ^a   Naliwaiko, Katya ^a   Kiss, Ágata ^a   Andreatini, Roberto ^a   Ferraz, Anete Curte ^a  

^a FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

^b Associacao Paranaense Dos Portadores de Parkinsonismo   (Brazil)

Author keywords

Depression; Fish oil; Omega 3 fatty acid supplementation; Parkinson's disease; Randomized controlled trial

Indexed keywords

AMANTADINE; ANTIDEPRESSANT AGENT; CATECHOL METHYLTRANSFERASE INHIBITOR; LEVODOPA; MINERAL OIL; OMEGA 3 FATTY ACID; PLACEBO; PRAMIPEXOLE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT;

ADULT; AGED; ARTICLE; BECK DEPRESSION INVENTORY; CLINICAL ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DOUBLE BLIND PROCEDURE; ERYTHROCYTE MEMBRANE; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MAJOR DEPRESSION; MALE; MONTGOMERY ASBERG DEPRESSION RATING SCALE; PARKINSON DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

AGED; ANTIDEPRESSIVE AGENTS; ANTIPARKINSON AGENTS; BRAZIL; COMBINED MODALITY THERAPY; COMORBIDITY; DEPRESSIVE DISORDER, MAJOR; DIETARY SUPPLEMENTS; DOUBLE-BLIND METHOD; FATTY ACIDS, OMEGA-3; FEMALE; HUMANS; LEVODOPA; MALE; MIDDLE AGED; MINERAL OIL; PARKINSON DISEASE; PERSONALITY INVENTORY; PILOT PROJECTS; PLACEBOS; PSYCHIATRIC STATUS RATING SCALES; TREATMENT OUTCOME;

EID: 54049153609     PISSN: 01650327     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jad.2008.03.008     Document Type: Article

References (50)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th Ed (1994), American Psychiatric Press, Washington, DC
2. Amorin P. Mini International Neuropsychiatric Interview (MINI): Validação de entrevista breve para diagnóstico de transtornos mentais. Rev. Bras. Psiquiatria 22 (2000) 106-115
3. Anand A., and Charney D.S. Norepinephrine dysfunction in depression. J. Clin. Psychiatry 61 Suppl.10 (2000) 16-24
4. Assies J., Lok A., Bockting C.L., Weverling G.J., Lieverse R., Visser I., Abeling N.G.G.M., Duran M., and Schene A.H. Fatty acids and homocysteine levels in patients with recurrent depression: an explorative pilot study. Prostaglandins Leukot. Essent. Fat. Acids 70 (2004) 349-356
5. Boston P.F., Bennetta A., Horrobin D.F., and Bennett C. Ethyl-EPA in Alzheimer's disease - a pilot study. Prostaglandins Leukot. Essent. Fat. Acids 71 (2004) 341-346
6. De Lau L.M.L., Bornedroek M., Witteman J.C.M., Hosnam A., Koudstaan P.J., and Breteler M.N.B. Dietary of fatty acids and the risk of Parkinson disease. Neurology 64 (2005) 2040-2045
7. De Vriese S.R., Christophe A.B., and Maes M. Lowered serum n-3 polyunsaturated fatty acid (PUFA) levels predict the occurrence of postpartum depression: further evidence that lowered n-PUFAs are related to major depression. Life Sci. 73 25 (2003) 3181-3187
8. Dratcu L., da Costa Ribeiro L., and Calil H.M. Depression assessment in Brazil. The first application of the Montgomery-Asberg Depression Rating Scale. Br. J. Psychiatry 150 (1987) 797-800
9. Edwards R., Peet M., Shay J., and Horrobin D. Omega-3 polyunsaturated fatty acid levels in the diet and in red blood cell membranes of depressed patients. J. Affect. Disord. 48 (1998) 149-155
10. Farooqui A.A., Horrocks L.A., and Farooqui T. Glycerophospholipids in brain: their metabolism, incorporation into membranes, functions, and involvement in neurological disorders. Chem. Phys. Lipids 106 (2000) 1-29
11. Folstein M.F., Folstein S.E., and McHugh P.R. Mini-Mental State: a practical method for grading the cognitive state of patients for clinician. J. Psychiatr. Res. 12 (1975) 189-198
12. Freeman M.P. Omega-3 fatty acids in psychiatry: a review. Ann. Clin. Psychiatry 12 (2000) 159-165
13. Freemantle E., Vandal M., Tremblay-Mercier J., Tremblay S., Blachere J., and Michel E. Omega-3 fatty acids, energy substrates, and brain function during aging. Prostaglandins Leukot. Essent. Fat. Acids 75 3 (2006) 213-220
14. Gorenstein C., and Andrade L. Validation of a Portuguese version of the Beck Depression Inventory and the State-Trait Anxiety Inventory in Brazilian subjects. Braz. J. Med. Biol. Res. 29 4 (1996) 453-457
15. Grenyer B.F.S., Crowe T., Meyer B., Owen A.J., Grigonis-Deane E.M., Caputi P., and Howe P.R.C. Fish oil supplementation in the treatment of major depression: A randomized double-blind placebo-controlled trial. Progr. Neuro-Psychopharmacol. Biol. Psychiatry 31 7 (2007) 1393-1396
16. Guy W. Clinical Global Impressions. ECDEU Assessment Manual for Psychopharmacology, revised (DHEW Publ No ADM 76-338) (1976), National Institute of Mental Health, Rockville, MD 218-222
17. Hakkarainem R., Partonem T., Haukka J., Virtamo J., Aalbanes D., and Lönnqvist J. Is low dietary intake of omega-3 fatty acids associated with depression?. Am. J. Psychiatry 161 (2004) 567-569
18. Hibbeln J.R. Fish oil consumption and major depression. Lancet 351 (1998) 1213
19. Hoehn M., and Yahr M. Parkinsonism: onset, progression and mortality. Neurology 17 5 (1967) 427-442
20. Julien C., Berthiaume L., Hadj-Tahar A., Rajput A.H., Bédard P.J., Di Paolo T., Julien P., and Calon F. Postmortem brain fatty acid profile of levodopa-treated Parkinson disease patients and parkinsonian monkeys. Neurochem. Int. 48 (2000) 404-414
21. Karege F., Perret G., Bondolfi M.G., Schwald M., Bertschy G., and Aubry J.M. Decreased serum brain-derived neurotrophic factor levels in major depressed patients. Psychiatry Res. 109 (2002) 143-148
22. Lin P.Y., and Su K.P. A meta-analytic review of double-blind, placebo-controlled trials of antidepressant efficacy of omega-3 fatty acids. J. Clin. Psychiatry 68 7 (2007) 1056-1061
23. Logan A. Omega-3 fatty acids and major depression: a primer for the mental health professional. Lipids in Health and Disease vol. 3 (2004) 25
24. Malamakis G., Tornaritis M., and Kafatos A. Depression and adipose essential polyunsaturated fatty acids. Prostaglandins Leukot. Essent. Fat. Acids 67 5 (2002) 311-318
25. Marangell L.B., Martinez J.M., Zboyan H., Kertz B., Kim F.S., and Puryear L. Double-blind, placebo-controlled study of the omega-3 fatty acid docosahexaenoic acid in the treatment of major depression. Am. J. Psychiatry 160 (2003) 996-999
26. Mercury M., Tschan W., Kehoe R., and Kuechler A. The Presence of Depression and Anxiety in Parkinson's disease. Dis. Mon. 53 (2007) 296-301
27. Montgomery S.A., and Asberg M. A new depression scale designed to be sensitive to change. Br. J. Psychiatry 134 (1979) 382-389
28. Moriguchi T., Geiner R.S., and Salem Jr. N. Behavioral deficits associated with dietary induction of decreased brain docosahexaenoic acid concentration. J. Neurochem. 75 (2000) 2563-2573
29. Morris M.C., Evans D.A., Tangney C., Bienias J., and Wilson R.S. Fish consumption and cognitive decline with age in a large community study. Arch. Neurol. 62 (2005) 1803-1804
30. Mossner R., and Riederer P. Allelic variation of a functional promoter polymorphism of the serotonin transporter and depression in Parkinson's disease. Parkinsonism Relat. Disord. 13 (2007) 62
31. Naliwaiko K., Araújo R.L.F., Da Fonseca R.V., Castilho J.C., Andreatini R., Bellissimo M.I., Oliveira B.H., Martins E.F., Curi R., Fernandes L.C., and Ferraz A.C. Effects of fish oil on the central nervous system: a new potencial antidepressant. Nutr. Neurosci. 7 (2004) 91-99
32. Nemets B., Stahl Z., and Belmaker R.H. Addition of omega-3 fatty acid to maintenance medication treatment for recurrent unipolar depressive disorder. Am. J. Psychiatry 159 (2002) 477-479
33. Nuyen J., Schellevis F.G., Satariano W.A., Spreeuwenberg P.M., Birkner M.D., Van Den Bos G.A.M., and Groenewegen P.P. Comorbidity was associated with neurologic and psychiatric disease: a general practice-based controlled study. J. Affect. Disord. 59 (2006) 1274-1284
34. Peet M., and Horrobin D.F. A dose-ranging study of the effects of ethyl-eicosapentaenoate in patients with ongoing depression despite apparently adequate treatment with standard drugs. Arch. Gen. Psychiatry 59 (2002) 913-919
35. Rabini R.A., Moretti N., Staffolani R., Salvolini E., Nanetti L., Franceschi C., and Mazzani L. Reduced susceptibility peroxidation of erythrocyte plasma membranes from centenarians. Exp. Gerontol. 37 (2002) 657-663
36. Raeder M., Steen V., Vollset S., and Bjelland I. Associations between cod liver oil use and symptoms of depression: The Hordaland Health Study. J. Affect. Disord. 101 1-3 (2007) 245-249
37. Ross B.M. W-3 Fatty acid deficiency in major depressive disorder is caused by the interaction between diet and a genetically determined abnormality in phospholipid metabolism. Med. Hypotheses 68 (2007) 515-524
38. Samadi P., Grégoire L., Rouillard C., Bédard P.J., Di Paolo T., and Lévesque D. Docosahexaenoic acid reduces levodopa-induced dyskinesis in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine monkeys. Ann. Neurol. 59 (2006) 282-288
39. Shulman L.M., Taback R.L., Rabistein A.A., and Weiner W.J. Non-recognition of depression and other non-motor symptoms in Parkinson's disease. Parkinsonism Relat. Disord. 8 (2002) 193-197
40. Silvers K.M., Woolley C., Hamilton F., Watts P., and Watson R. Randomized double-blind placebo-controlled trial of fish oil in the treatment of depression. Prostaglandins Leukot. Essent. Fat. Acids 72 (2005) 211-218
41. Su K.P., Huang S.Y., Chiu C.C., and Shen W.W. Omega-3 fatty acids in major depressive disorder. A preliminary double-blind, placebo-controlled trial. Eur. Neuropsychopharmacol. 13 (2003) 267-271
42. Tanskanen A., Hibbeln J.R., Hintikka J., Haatainen K., Honlalampik K., and Viinamaki H. Fish oil consumption, depression and suicidality in a general population. Arch. Gen. Psychiatry 58 (2001) 512-513
43. Taylor T., Jefferis G.S., Koop M., Hill B.C., Hastie T., Heit G., and Bronte-Stewart H.M. Quantitative measurements of alternating finger tapping in Parkinson's disease correlate with UPDRS motor disability and reveal the improvement in fine motor control from medication and deep brain stimulation. Mov. Disord. 20 (2005) 01286-01298
44. Teive, H.A.G., Meneses, M.S., 2003. Doença de Parkinson. 1. ed. Rio de Janeiro: Guanabara Koogan.
45. Timonen M., Horrobin D., Jokelainen J., Laitinen J., Herva A., and Rasanen P. Fish consumption and depression: the Northern Finland 1966 birth cohort study. J. Affect. Disord 82 (2004) 447-452
46. Tolosa E., Compta Y., and Gaig C. The premotor phase of Parkinson's disease. Parkinsonism Relat. Disord. 13 (2007) S2-S7
47. Vajda F.J.E., and Solinas C. Current approaches to management of depression in Parkinson's disease. J. Clin. Neurosci. 12 7 (2005) 739-743
48. Wichowicz H.M., Slawek J., Derejko M., and Cubala W. Factors associated with depression in Parkinson's disease: a cross-sectional study in a Polish population. Eur. Psychiatry 21 (2006) 516-520
49. Youdim K.A., Martin A., and Joseph J.A. Essential fatty acids and the brain: possible health implications. Int. J. Dev. Neurosci. 18 (2000) 383-399
50. Ziemssen T., and Reichmann H. Non-motor dysfunction in Parkinson's disease. Parkinsonism Relat. Disord. 13 (2007) 323-332